Related Experiment Videos
Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients
P Ambrosi1, M F Aillaud, G Habib
1Department of Cardiology, Hôpital de la Timone, Marseille, France.
Insights
Fluvastatin therapy significantly reduced plasma thrombomodulin levels in heart transplant recipients, indicating improved endothelial injury. This cholesterol-lowering drug shows potential for managing vascular health post-transplant.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac transplant recipients often exhibit elevated markers of endothelial activation or injury.
- Baseline levels of thrombomodulin and von Willebrand factor antigen are higher in these patients compared to healthy controls.
Purpose of the Study:
- To evaluate the impact of a 4-week fluvastatin treatment on plasma markers of endothelial activation and injury in heart transplant recipients.
Main Methods:
- A randomized, placebo-controlled, double-blind, cross-over study was conducted.
- Twenty heart transplant recipients participated in the study.
- Plasma markers including thrombomodulin, von Willebrand factor, and lipids were assessed before and during treatment.
Main Results:
- Fluvastatin therapy led to a significant 21% reduction in plasma total cholesterol (p = 0.0001).
- A significant decrease in plasma thrombomodulin was observed (66.7 ng/ml on placebo vs. 58.8 ng/ml on fluvastatin, p < 0.001).
- No significant effects were noted on creatininemia, plasma cyclosporine, PAI-1, tPA antigen, or von Willebrand factor.
Conclusions:
- Fluvastatin therapy rapidly improves endothelial injury in heart transplant recipients, as evidenced by decreased thrombomodulin levels.
- The study suggests a potential benefit of fluvastatin in managing endothelial dysfunction in this patient population.
Abstract:
We conducted a randomized, placebo controlled, double-blind, cross-over study, to assess the effects of a 4-week fluvastatin therapy on plasma markers of endothelial activation or injury in 20 transplanted heart recipients. The levels of thrombomodulin and von Willebrand factor antigen were higher at baseline in cardiac transplant recipients than in age and sex-matched healthy controls. Plasma total cholesterol showed a 21% reduction on fluvastatin therapy (p = 0.0001). Fluvastatin treatment had no significant effect on creatininemia, plasma cyclosporine, PAI-1 antigen, PAI-1 activity, tPA antigen, and Von Willebrand factor. However, fluvastatin produced a significant decrease of plasma thrombomodulin (66.7 ng/ml on placebo versus 58.8 ng/ml on fluvastatin, p <0.001), suggesting a rapid improvement of endothelial injury in these patients.